Abstract
The second-generation everolimus-eluting stents (EES) are loaded with everolimus, which is a powerful analog of sirolimus; the drug carrier consists of a thin layer of durable and biocompatible fluorocopolymer, and the platform is made of cobalt-chromium alloy to allow thinner struts as well as to enhance stent radial strengh, delivery, and percutaneous coronary intervention success rates. EES are safe and efficient for the treatment of coronary artery disease in a wide range of anatomic settings, where several trials show EES superior to paclitaxel-eluting stents (PES); however, the superiority of EES over sirolimus-eluting stents (SES) is not so clear as over PES. In specific profiles of subjects such as diabetic patients, women, and patients presenting acute myocardial infarction (AMI), EES are also safe and efficient. In diabetic patients, the expected superiority of EES over PES and SES has not been confirmed. EES are equally safe and effective for women as for the general population. In the AMI setting, EES promote safety and efficacy outcomes similar to those found in non-AMI patients, as well as lower stent thrombosis rates in comparison with SES and PES. In conclusion, second-generation EES are safe and efficient for treatment of coronary artery disease in a wide range of anatomic and clinical settings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical Medicine Reviews in Cardiology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
